Sormani MP, Häring DA, Kropshofer H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, 277.
RAS-ALS: Effectiviteit van rasagiline in subgroepen
mrt 2024 | Bewegingsstoornissen